TrialAnnals of the rheumatic diseases2011

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.

Peter C Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.